Difference between revisions of "Team:ETH Zurich"

Line 53: Line 53:
 
         <br>
 
         <br>
 
         <br>
 
         <br>
−
         We need more specific therapies because current approaches result in many side-effects. Thats why we invented CATE, the first all-in-one  
+
         We need more specific therapies because current approaches result in many side-effects. That's why we invented CATE, the first all-in-one  
 
         living cancer therapeutic with an integrated two-step safety mechanism.  
 
         living cancer therapeutic with an integrated two-step safety mechanism.  
 
         <br>
 
         <br>
 
         <br>
 
         <br>
−
         That's why we created CATE: Cancer-Targeting <i>E. coli</i>.
+
         That's why we created CATE: Cancer-Targeting <i>E. coli</i>. A living cure to a living disease.
 
         <br>
 
         <br>
 
         <br>
 
         <br>
Line 77: Line 77:
 
       <br>
 
       <br>
 
       <br>
 
       <br>
−
      We are engineering E. coli Nissle to carry a MRI
+
        It features two safety checkpoint mechanisms to ensure only tumor cells are damaged.
−
      contrast and a cytotoxic agent so it can deliver both components to tumor sites.
+
 
       <br>
 
       <br>
 
       <br>
 
       <br>
−
       <a href="https://2017.igem.org/Team:ETH_Zurich/Description" class="more">Project description</a>
+
       <a href="https://2017.igem.org/Team:ETH_Zurich/Description" class="more">Description</a>
 
     </div>
 
     </div>
 
      
 
      
Line 111: Line 110:
  
 
<section id="second" class="step invert">
 
<section id="second" class="step invert">
−
    <div>
+
  <div>
−
        <p>CATE consists of the non-pathogenic bacterium  E. coli Nissle that has the intrinsic ability to home specifically in tumors.<br><br> We are engineering E. coli Nissle to carry a MRI contrast and a cytotoxic agent so it can deliver both components to tumor sites.</p>
+
  </div>
−
    </div>
+
−
    <img src="https://static.igem.org/mediawiki/2017/0/02/T--ETH_Zurich--Ec.png" class="Ec">
+
−
    <a href="https://2017.igem.org/Team:ETH_Zurich/Description" class="more">Project description</a>
+
 
</section>
 
</section>
  

Revision as of 09:43, 19 October 2017

Cancer kills over 8 million people every year. That's the entire population of Switzerland!

We need more specific therapies because current approaches result in many side-effects. That's why we invented CATE, the first all-in-one living cancer therapeutic with an integrated two-step safety mechanism.

That's why we created CATE: Cancer-Targeting E. coli. A living cure to a living disease.

Learn more
CATE consists of the non-pathogenic bacterium E. coli Nissle that has the intrinsic ability to home specifically in tumors.

It features two safety checkpoint mechanisms to ensure only tumor cells are damaged.

Description
CATE is administered intravenously, travels through the blood and colonizes tumors where the bacteria form a highly dense layer between the live and dead zone of the tumor.

The high density of bacterial cells and the overproduction of lactate by the tumor together activate the first steps of CATE.

Design